Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Effects of raloxifene on fracture risk in women with breast cancer examined
October 20th, 2005
The effects of raloxifene on fracture risk in women with breast cancer was examined. "The multicenter, double-blind Continuing Outcomes Relevant to Evista (CORE) trial assessed the effects of raloxifene on breast cancer for 4 additional years beyond the 4-year Multiple Outcomes of Raloxifene Evaluation (MORE) osteoporosis treatment trial," reported investigators in the United States. "In CORE, placebo-treated women from MORE continued with placebo (n=1286), whereas those previously given raloxifene (60 or 120 mg/day) received raloxifene 60 mg/day (n=2725). As a secondary endpoint, new nonvertebral fractures were analyzed as time-to-first event in...
Source: Women's Health Weekly (2005-10-20)
|
